The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.

CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.

An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.

CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.

The $220,000 award will be directed to a Phase I clinical trial that will investigate the effectiveness of CAR T-cell therapy to treat AML.

A bone marrow transplant saved Kaleo’s life. Today, he’s a dancing machine. His success story is an example of CHOP’s expertise in the field of cellular therapy.

Charles Phillips, MD, a CHOP fellow, recounts his experience caring for a cancer patient and the many firsts it brought to the both of them.

With the majority of Hodgkin lymphoma patients surviving their disease, the focus has turned to minimizing the long-term effects of treatment while maintaining excellent cure rates.

Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.

After four years of battling leukemia, Mitch was no longer responding to his cancer therapy. But new immunotherapy options at Children's Hospital gave him another chance to be a kid.